Status and phase
Conditions
Treatments
About
GIM-122 is a first-in-class, humanized immunoglobulin G1 kappa dual functioning monoclonal antibody (DFA). This phase 1 / 2 study plans to evaluate the safety, tolerability, pharmacokinetics and clinical efficacy of intravenous (IV) administration of GIM-122 in adults with advanced malignancies.
Full description
This is a Phase 1/2, open label, first-in-human (FIH), multicenter, dose escalation study with enrichments and dose expansion cohorts at RP2D, designed to evaluate the safety, tolerability, PK, pharmacodynamics, and preliminary antitumor activity of GIM-122 administered as a single agent in adults with advanced solid malignancies. This study will be conducted in 2 parts: Phase 1 or Part A (dose escalation and enrichment) and Phase 2 or Part B (dose optimization and cohort expansion).
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
General
Exclusion criteria
General
Treatment-specific Exclusion Criteria
Primary purpose
Allocation
Interventional model
Masking
111 participants in 1 patient group
Loading...
Central trial contact
LumaBridge CRO
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal